Loading…
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-155M | $-138M | $-107M | -34.4% | - | - |
| 2024 | $0M | $-82M | $-68M | $-75M | -13.8% | - | - |
| 2023 | $0M | $-40M | $-52M | $-46M | 34.9% | - | - |
| 2022 | $0M | $-38M | $-38M | $-32M | 38.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 37.66 | 39.89 | 82.39 | 155.60 |
| Operating Income | -37.66 | -39.89 | -82.39 | -155.60 |
| EBITDA | -37.72 | -39.87 | -82.33 | -155.50 |
| EBIT | -37.73 | -39.89 | -82.39 | -155.60 |
| Pretax Income | -37.84 | -51.98 | -67.81 | -137.73 |
| Tax Provision | 0 | 0.01 | 0.19 | 0.22 |
| Net Income | -37.84 | -51.98 | -68 | -137.95 |
| Net Income Common Stockholders | -37.84 | -51.98 | -68 | -137.95 |
| Total Expenses | 37.66 | 39.89 | 82.39 | 155.60 |
| Interest Expense | 0.11 | 0 | 0 | 0 |
| Interest Income | 0 | 1.31 | 14.58 | 17.87 |
| Research And Development | 31.31 | 30.62 | 63.62 | 125.10 |
| Selling General And Administration | 6.34 | 9.27 | 18.77 | 30.51 |
| Normalized EBITDA | -37.72 | -39.87 | -82.33 | -155.50 |
| Normalized Income | -37.84 | -51.98 | -68 | -137.95 |
| Basic EPS | -2.45 | -1.53 | -4.05 | -2.52 |
| Diluted EPS | -2.45 | -1.53 | -4.05 | -2.52 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -37.84 | -51.98 | -68 | -137.95 |
| Reconciled Depreciation | 0.01 | 0.02 | 0.06 | 0.10 |
| Net Interest Income | -0.11 | 1.31 | 14.58 | 17.87 |
| Net Income From Continuing And Discontinued Operation | -37.84 | -51.98 | -68 | -137.95 |
| Total Operating Income As Reported | -37.66 | -39.89 | -82.39 | -155.60 |
| Diluted Average Shares | 15.44 | 33.98 | 16.81 | 54.68 |
| Basic Average Shares | 15.44 | 33.98 | 16.81 | 54.68 |
| Diluted NI Availto Com Stockholders | -37.84 | -51.98 | -68 | -137.95 |
| Net Income Including Noncontrolling Interests | -37.84 | -51.98 | -68 | -137.95 |
| Net Income Continuous Operations | -37.84 | -51.98 | -68 | -137.95 |
| Other Income Expense | -0.08 | -13.40 | 0 | 0 |
| Other Non Operating Income Expenses | -0.08 | -13.40 | 0 | 0 |
| Net Non Operating Interest Income Expense | -0.11 | 1.31 | 14.58 | 17.87 |
| Interest Expense Non Operating | 0.11 | 0 | 0 | 0 |
| Interest Income Non Operating | 0 | 1.31 | 14.58 | 17.87 |
| General And Administrative Expense | 6.34 | 9.27 | 18.77 | 30.51 |
| Other Gand A | 2.54 | 9.27 | 6.22 | 9.93 |
| Salaries And Wages | 3.80 | 5.82 | 12.54 | 20.58 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc.this co. | BCAX | $1.4B | - | 2.89 | -34.4% | -6.30 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | - | 3.57 | -36.9% | -6.82 |
| Alphatec Holdings, Inc. | ATEC | $1.4B | - | 112.05 | -1153.7% | 95.59 |
| ArriVent BioPharma, Inc. | AVBP | $1.4B | - | 4.15 | -54.1% | - |
| AtriCure, Inc. | ATRC | $1.4B | - |
| 2.77 |
| 0.0% |
| 114.65 |
| Biohaven Ltd. | BHVN | $1.4B | - | 23.47 | -1418.8% | -1.93 |
| NovoCure Limited | NVCR | $1.4B | - | 3.94 | -40.0% | -8.57 |
| Ardent Health, Inc. | ARDT | $1.4B | 10.03 | 1.07 | 8.1% | 7.02 |
| Pulse Biosciences, Inc. | PLSE | $1.4B | - | 17.00 | -90.2% | -17.15 |
| Peer Median | - | 10.03 | 4.05 | -47.1% | -1.93 | |